EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cardiotoxicity associated with antineoplastic agents: a pharmacovigilance study based on FDA adverse event reporting system

Xiaohan Qiu iD, Qinxiao Li, Yiyin Rong, Longyu Wang, Jiahan Ke, Min Wang, Huasu Zeng, Jun Gu iD

Therapeutic Advances in Drug Safety · 2025-12 · 16

DOI: 10.1177/20420986251401122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Drug Safety, online erschienen am 11.12.2025. Verfasst von Xiaohan Qiu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, the project of Shanghai Science and Technology Commission, Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiovascular adverse events represent critical complications of antineoplastic therapy with profound implications for cancer survivorship and treatment outcomes. Despite the clinical significance, comprehensive pharmacovigilance data characterizing distinctive cardiotoxicity profiles across modern cancer therapeutics remain limited.

Objectives

This investigation systematically analyzes cardiotoxicity patterns associated with antineoplastic agents using the FDA Adverse Event Reporting System (FAERS) database to inform evidence-based cardiovascular monitoring strategies.

Design

A retrospective pharmacovigilance study utilizing disproportionality analysis and time-to-onset evaluation.

Methods

We conducted a comprehensive analysis of FAERS data spanning 2004–2024, employing validated disproportionality metrics including reporting odds ratio (ROR) and proportional reporting ratio (PRR) to detect significant drug-event associations. Advanced time-to-onset analysis revealed temporal patterns of cardiotoxicity development across therapeutic classes. Statistical significance was defined as ROR >1 with 95% confidence intervals excluding 1.0, and PRR >2 with chi-square >4.

Results

Analysis of 18,289,374 reports identified 51,402 cases of antineoplastic-related cardiovascular toxicity, demonstrating distinct class-specific patterns. Anthracyclines exhibited profound associations with structural cardiac damage (doxorubicin-cardiomyopathy: ROR = 20.64, 95% CI: 19.87–21.45). Immune checkpoint inhibitors demonstrated unprecedented immune-mediated cardiac inflammation (pembrolizumab-myocarditis: ROR = 245.36, 95% CI: 218.42–275.88). Fluoropyrimidines showed distinctive vasospastic effects (5-fluorouracil-Prinzmetal angina: ROR = 18.27, 95% CI: 14.72–22.69). Critical temporal patterns emerged: fluoropyrimidines caused early-onset cardiotoxicity (median: 11 days, IQR: 4–28), anthracyclines showed intermediate onset (doxorubicin median: 64 days, IQR: 21–156; epirubicin median: 72 days, IQR: 28–168), while mitoxantrone demonstrated delayed effects (median: 457 days, IQR: 182–891). Cardiogenic shock emerged as the most lethal manifestation with a 43.08% mortality rate (95% CI: 40.12–46.14).

Conclusion

This landmark pharmacovigilance study reveals previously uncharacterized temporal and mechanistic patterns of antineoplastic cardiotoxicity, providing an essential evidence-based framework for cardiovascular monitoring strategies. The findings highlight critical intervention windows: immediate monitoring for fluoropyrimidines, intermediate surveillance for anthracyclines (2–6 months), and extended follow-up for agents like mitoxantrone (>12 months). These insights support the development of risk-stratified cardio-oncology protocols tailored to specific therapeutic classes.

Schlagwörter

Stichwörter der Autor:innen

FAERSadverse eventsantineoplastic agentscancer treatmentcardio-oncologycardiotoxicitypharmacovigilance

Autor:innen und Institutionen

  • Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Northwest Hospital, the Second Hospital Affiliated to Xi'an Jiaotong University, Xi'an, China.
  • Division of Nephrology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200001, China.

ORCID-Profile: Xiaohan Qiu, Jun Gu

Förderung

  • National Natural Science Foundation of China
  • the project of Shanghai Science and Technology Commission
  • Shanghai Municipal Health Commission
  • Clinical Research Program

Zitieren

APA

Qiu, X., Li, Q., Rong, Y., Wang, L., Ke, J., Wang, M., Zeng, H., & Gu, J. (2025). Cardiotoxicity associated with antineoplastic agents: a pharmacovigilance study based on FDA adverse event reporting system. Therapeutic Advances in Drug Safety, 16. https://doi.org/10.1177/20420986251401122

Vancouver

Qiu X, Li Q, Rong Y, Wang L, Ke J, Wang M, et al. Cardiotoxicity associated with antineoplastic agents: a pharmacovigilance study based on FDA adverse event reporting system. Therapeutic Advances in Drug Safety. 2025;16. doi:10.1177/20420986251401122

BibTeX
@article{Qiu2025,
  author = {Qiu, Xiaohan and Li, Qinxiao and Rong, Yiyin and Wang, Longyu and Ke, Jiahan and Wang, Min and Zeng, Huasu and Gu, Jun},
  title = {Cardiotoxicity associated with antineoplastic agents: a pharmacovigilance study based on FDA adverse event reporting system},
  journal = {Therapeutic Advances in Drug Safety},
  year = {2025},
  volume = {16},
  doi = {10.1177/20420986251401122}
}
Kostenlos starten →